MedTrace Logo

CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH

NCT03726398 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2025-02-20

No results posted yet for this study

Summary

Patients with interstitial lung disease (ILD) and scleroderma who develop pulmonary hypertension (PH) do not fit well into the current classification system and treatments for pulmonary hypertension. This study aims to better understand patients with ILD-PH and scleroderma and to determine if treatment with Macitentan is beneficial.

Conditions

Interventions

DRUG

Opsumit 10 Mg Tablet

Oral tablet taken once daily

Sponsors & Collaborators

  • National Jewish Health

    collaborator OTHER

  • University of Pittsburgh

    collaborator OTHER

  • Franz Rischard, DO

    lead OTHER

Principal Investigators

  • Franz P. Rischard, DO · University of Arizona

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2020-08-03
Completion
2020-08-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03726398 on ClinicalTrials.gov